Skip to content
Screener

Amylyx Pharmaceuticals, Inc. AMLX Q4 2025 Annual earnings

Reported March 3, 2026 · Before market open

Revenue-
EPS-$0.30Beat by $0.01
EPS estimate-$0.31

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$59.4K
EPS estimate-$0.38

Financials

Q4 2025

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$36.6M+10.0%
Net income-$33.0M+12.1%
EPS (diluted)-$0.28+48.1%

Balance sheet

See full
Cash & equivalents$226.7M+193%
Total debt$6.0M+201%
Total equity$305.3M+85.3%
Total assets$332.6M+71.8%

Cash flow

See full
Operating cash flow-$27.9M+52.7%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.33B+412%
Enterprise value$1.11B+502%

Returns & leverage

See full
Return on equity-61.6%-17.3pp
Debt / equity0×0.0×
Current ratio14.3×+7.6×

FAQ

When did Amylyx Pharmaceuticals, Inc. report Q4 2025 earnings?
Amylyx Pharmaceuticals, Inc. (AMLX) reported Q4 2025 earnings on March 3, 2026 before market open.
What were Amylyx Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Amylyx Pharmaceuticals, Inc. reported revenue of - and eps of $-0.30 for Q4 2025.
Did Amylyx Pharmaceuticals, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.31 by $0.01.
How did Amylyx Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $665.0K a year earlier and eps grew 45.5% from $-0.55.
Where can I find Amylyx Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-086629) and the 10-K periodic report (0001193125-26-086645) directly on SEC EDGAR. The filing index links above go to sec.gov.